Back to Top
Enews Now
September 2017
In the News
How Th2A Cells Could Lead to the Ability to Predict Allergy

A team of researchers from the Benaroya Research Institute in Seattle published their findings on a cell group only present in people with allergies called Th2A cells.
News Briefs
FDA Acknowledges Qualified Health Claim on Early Peanut Introduction and Reduced Risk of Allergy
The new claim, which can used by manufacturers immediately, signals a major change in food labeling regarding peanut allergy in infants. Read more »
FDA Warning Issued for Select Alcohol Pads and Antiseptic Towelettes Due to Lack of Sterility Assurance
The FDA has issued an alert for alcohol pads and antiseptic towelettes manufactured by Foshan Flying Medical Products. Read more »
Are You Expected to Participate in Quality Reporting in 2017?
Now is the time to educate yourself and determine if you need to report in 2017. Read more »
Web Tips

An Introduction to Biologic Therapies for Your Patients

Biologic therapies are becoming more popular for patients with allergic and immunologic diseases. As they ask more questions, point them to the libraries in the Condition & Treatments section of and have them look for our new series of articles on biologic therapies written by AAAAI member Jonathan Corren, MD. The first article in the series is “An Introduction to Biologic Therapies” and it’s available in both English and Spanish. The next article will be coming soon.

From the President

Dear Colleagues,

What is the AAAAI doing to look out for you and the allergy/immunology (A/I) specialty? I’d like to use this space to describe several ongoing efforts. The first four are being spearheaded by the AAAAI’s Advocacy Committee while the final item involving Maintenance of Certification (MOC) is taking place at the Executive Committee level.


Our work to address proposed standards and regulations impacting in-office compounding of allergen extract for immunotherapy has by no means ended. We are still heavily involved in this issue.

In fact, Andrew W. Murphy, MD, FAAAAI, Chair of the AAAAI’s Office of Practice Management and Advocacy Committee member, was recently invited by the United States Pharmacopeia (USP) to represent A/I on a small work group of physicians representing specialties impacted by the proposed update to Chapter 797. The work group provided feedback for the development of definitions of “administration” of compounded substances and “urgent use.”